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Abstract 
Background: The usefulness of lower urinary tract symptoms (LUTS) as mortality 
risk factors remains unclear. Repeated assessments are required to take into account 
symptom fluctuation and de novo symptom appearance. The study objective was to 
evaluate mortality in relation to three urinary storage symptoms — urgency, daytime 
frequency and nocturia — in middle-aged and elderly men, considering also other 
time-varying factors during follow-up. 
Methods: A mail survey of a population-based cohort of men initially aged 50, 60 and 
70 years was conducted in Finland in 1994, 1999, 2004 and 2009. The questionnaire 
included assessments of LUTS based on the Danish Prostatic Symptom Score and 
comorbidities. The men were followed up for mortality through the population 
registry through 2014. LUTS-related hazard ratios (HR) were analyzed with time-
dependent Cox regression adjusted for the year of birth and comorbidities using 
variable values updated every five years. Sensitivity analyses were conducted using 
values of all variables fixed to the baseline assessment of 1994. 
Results: Of the 1332 eligible men with data on LUTS from each preceding survey, 
514 (38.6%) died during the 21-year follow-up. In time-dependent analyses, daytime 
frequency and nocturia were significantly associated with increased mortality: the 
adjusted HR was 1.42 (95%CI 1.11-1.83) for daytime frequency, 1.38 (1.07-1.79) for 
nocturia and 1.19 (0.94-1.50) for urgency. In sensitivity analyses with fixed baseline 
characteristics, only nocturia was suggestively associated with an increased risk of 
death: the adjusted HR was 1.09 (0.84-1.42) for daytime frequency, 1.41 (0.99-2.02) 
for nocturia and 0.94 (0.52-1.68) for urgency. 
Conclusions: Among aging men, LUTS are more accurate predictors of short-term 
than longer-term mortality risk. Repeated assessments are needed to detect clinically 
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 ill health. Accordingly, men  relevant and persistent symptoms, often associated with
 with daytime frequency or nocturia exhibit a 1.4-fold risk of death and therefore, 
 should be evaluated for underlying comorbidity. 
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Introduction 
The number of patients presenting with lower urinary tract symptoms (LUTS) is 
increasing as the population ages. LUTS are divided into two broad categories: storage 
symptoms (daytime urinary frequency, nocturia, urgency, urinary incontinence) and 
voiding symptoms (incomplete emptying, intermittency, slow stream, hesitancy). An 
important factor for male LUTS is bladder outlet obstruction (BOO), typically caused 
by benign prostatic hyperplasia (BPH) — a condition affecting more than half of men 
aged over 50 years [1]. Although various interventions can alleviate bothersome 
LUTS, persistent or recurrent symptoms are frequent despite treatments such as 
surgery for BOO [2,3]. This is explained by the multifactorial etiology of LUTS: age-
related physiological changes, various lifestyle factors and medical conditions affect 
lower urinary tract and renal function. Of the various LUTS, comorbidities are 
particularly important for urinary storage symptoms [4,5]. 
As men with LUTS tend to be older and are more likely to have comorbidities than 
asymptomatic men, they are potentially at a higher risk of death. To reliably assess the 
impact of LUTS on mortality, careful consideration of various confounding factors is 
warranted. Longitudinal studies have suggested LUTS to predict development of 
cardiovascular diseases, albeit with some inconsistency [6,7]. In previous longitudinal 
studies, LUTS have commonly been assessed either by using pre-defined cutoff values 
of various symptom scores or by retrospectively screening medical records for 
diagnosis codes without distinguishing individual symptoms. In the case of nocturia — 
the only symptom for which an association with mortality has been addressed in 
several earlier studies — the heterogeneity among previous results may reflect 
variation in methods, follow-up times and age distributions [8], as the natural course 
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of LUTS may vary considerably between populations [9-11]. Hypothetically, the 
confidence of the estimates on LUTS-related mortality could be strengthened by 
taking into account the incidence and remission of symptoms and comorbidities in the 
course of follow-up. Therefore, the aim of this study is to analyze the impact of three 
common storage LUTS – urinary urgency, daytime frequency and nocturia –  on all-
cause mortality during 21 years of follow-up utilizing repeated assessments in a 
population-based cohort of middle-aged and elderly men 
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Subjects and Methods 
Tampere Aging Male Urologic Study 
A population-based cohort study focusing on urological symptoms and sexual 
functioning among middle-aged and elderly men was launched in Pirkanmaa County, 
Finland in 1994, with repeat rounds in 1999, 2004 and 2009. Study details have been 
published previously [12,13]. Briefly, a sample of 3143 men was identified from the 
Finnish Population Register in 1994, comprising all men born in 1924, 1934 or 1944 
residing in the study area at the baseline. Self-administered questionnaires were mailed 
to the men in the study population at all rounds. Non-responders were reminded with a 
second mailing after three months. The questionnaire comprised items on frequency 
and bother of LUTS, major health conditions and medications, as well as 
sociodemographic, anthropometric, and lifestyle factors. An exemption from ethical 
review was granted by the ethics committee of the Pirkanmaa Hospital District 
(tracking number 99050). 
Measures 
The frequencies of LUTS were assessed using the Danish Prostatic Symptom Score 
(DAN-PSS-1) [14], consistent with the International Continence Society definitions 
[15]. An exception was made in 1994 in the assessment of urgency, where a modified 
question translated back from Finnish to English was as follows: “Is your need to 
urinate so urgent that it is difficult to hold it back until you reach the toilet?”, which 
was since modified and used at subsequent the rounds in 1999, 2004 and 2009 as “Do 
you experience an imperative (strong) urge to urinate?”. The response options were 
never—rarely—often—always. The question concerning daytime frequency was 
“What is the longest interval between each voiding, from when you wake up until you 
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go to bed?” with response options of more than 3 hours—2-3 hours—1-2 hours—less 
than 1 hour. The question concerning nocturia was “How many times do you have to 
urinate per night?” with response alternatives of none—1 or 2 times—3 or 4 times—5 
times or more. The preceding four-week period was used as the reference time frame 
for the questions. As only moderate and severe LUTS are clinically meaningful, these 
were compared with mild or absent symptoms after recoding each symptom into a  
binary variable [16]. Accordingly, urgency was categorized asFor the analysis, each  
symptom was recoded into a binary variabl “e:often or always” vs. “never or rarely” and 
daytime frequency as nine or more vs. eight or less voids per day. Based on the response 
alternatives for nocturia question in DAN-PSS, the case definition of three or more vs. two 
or less voids per night was considered to most adequately detect 
clinically relevant cases with best comparability to the generally acknowledged case 
definition for significant nocturia of two or more more voids per night [8,17].  no or 
mild vs. moderate or severe symptoms (the first two versus the two latter options). The 
men were followed up for mortality through the population registry until the end of 
2014. Information on the time and cause of death was obtained by a deterministic 
linkage with the unique personal identification number as the key. 
Statistical Analyses 
For analyses of mortality, we included men who had answered questions for LUTS at 
every survey in 1994-2009 (while alive) and for comorbidities at least in the 1994 
survey. To adjust the analyses for confounders, variables with well-established 
prognostic importance were selected for regression analyses. These variables, of which 
many are also known to be associated with LUTS, included age, marital status 
(married or cohabiting versus single or widowed), body mass index (BMI , ≤25 versus 
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>25 kg/m2), current smoking (yes/no), alcohol consumption (≤150 g/week vs. >150
g/week), previous diagnosis of diabetes, hypertension, cardiac disease, pulmonary 
disease, cerebrovascular disease, cancer and neurological disease. 
Univariate Cox regression analyseis weares performed for each urinary symptom and 
potential prognostic variable. To assess their independent effects on mortality and to 
test the magnitude and direction of confounding, all All variables were included in the 
multivariable-adjusted analyses modelsto assess their independent effects on each  
LUTS. All characteristics were treated as time-dependent categorical variables in the  
regression model. “Last observation carried forward” method [16] was used for 
comorbidities with missing values in the following rounds. Parallel analyses were 
made for each LUTS to provide time-varying hazard ratios using variable values 
updated every five years (time-dependent analysis). To further examine the effect of 
fluctuation of LUTS and associated comorbidities, and for easier comparison to 
previous studies, sensitivity analyses were conducted using values of all variables 
fixed to the baseline assessment (1994) and Kaplan-Meier curves were used to 
graphically represent these associations. Furthermore, interaction terms were evaluated 
in the regression models of the association of each LUTS with mortality, and subgroup 
analyses were conducted for the variables with a significant interaction. For all 
statistical analyses, SPSS version 23 was used. 
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Results 
A total of 2198 questionnaires (70 %) were returned in 1994, 2133 (75%) in 1999, 
1905 (76%) in 2004 and 1424 (66%) in 2009 of whom 1332 were eligible for the study 
by providing sufficient data for the analyses, i.e. having answered questions regarding 
LUTS at every survey (while alive). Regarding the age distribution of the included 
men, the proportions were 41%, 36% and 23% for men aged 50, 60 and 70 at the 
baseline, respectively. Men with LUTS were generally older than those without LUTS 
and virtually all medical conditions were more frequent among men with LUTS (Table 
1, Suppl. Table 1). 
The symptoms showed substantial fluctuation with a decreasing trend for daytime 
frequency with a prevalence of 10.8% at the baseline and 7.3% at 15 years and an 
increasing trend for nocturia, with prevalence 3.8% at the baseline and 8.9% at 15 
years. Reflecting the modified question in the assessment of urgency in 1994, its 
prevalence was materially lower at the baseline (1.8%) compared to the subsequent 
rounds (14.5% at five, 17.8% at 10 and 19.1% at 15 years) (Fig. 1). 
Analyses of Mortality 
During the 21-year follow-up, 514 men died, of whom 139 during the first, 126 during 
the second and 112 during the third 5-year period and 137 during the last period of six 
years. The overall mortality was 10.4% at five years, 19.9% at 10 years, 28.3% at 15 
years and 38.6% at 21 years. Mortality was higher among men with LUTS at every 
stage of follow-up (Fig. 1). In unadjusted time-dependent analyses, each of the studied 
storage symptoms was strongly associated with an increased risk of death: the HR was 
1.71 (95% CI 1.36-2.14) for urgency, 1.95 (1.52-2.49) for daytime frequency and 2.31 
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(1.79-2.98) for nocturia (Table 2). In unadjusted analyses with fixed baseline 
characteristics, daytime frequency and nocturia were significantly associated with an 
increased risk of death, while urgency showed no significant association: HR 1.43 
(1.11-1.84) for daytime frequency, 2.56 (1.81-3.63) for nocturia and 1.52 (0.86-2.69) 
for urgency (Fig. 2, Table 2). 
In multivariable-adjusted time-dependent analyses, daytime frequency and nocturia 
remained significantly associated with an increased risk of death, while urgency 
showed only a suggestive association: the adjusted HR was 1.42 (1.11-1.83) for 
daytime frequency, 1.38 (1.07-1.79) for nocturia and 1.19 (0.94-1.50) for urgency 
(Table 2, Suppl. Table 2). In multivariable-adjusted analyses with fixed baseline 
characteristics, only nocturia was suggestively associated with an increased risk of 
death: the adjusted HR was 0.94 (0.52-1.68) for urgency, 1.09 (0.84-1.42) for daytime 
frequency and 1.41 (0.99-2.02) for nocturia (Table 2, Suppl. Table 3). 
In the regression analyses, the majority of the studied covariates – older age, marital 
status of single/divorced or widowed, current smoking, diabetes, cardiac disease,  
cerebrovascular disease, cancer and neurological disease – were indepedently 
associated with an increased risk of death (Suppl. Tables 2,3). In multivariable-
adjusted analyses including interaction termsthe regression analysis, a significant  
interaction was found between smoking and urgency (p=0.02), as well as between  
previously diagnosed cardiac disease and urgency (p=0.04). The effect of urgency was  
suggestively stronger among non-smokers compared to smokers (HR 1.46, 1.12-1.91 vs. 
0.73, 0.45-1.20) and among those without a diagnosed cardiac disease compared to  those 
with a diagnosis (HR 1.30, 0.95-1.79 vs. 1.04, 0.73-1.48) (Table 3). The effects 
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of daytime frequency and nocturia showed no significant differences between any 
subgroups. (Suppl. Table 4). 
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Discussion 
Due to the fluctuating nature of the symptoms and related comorbidities, the impact of 
LUTS as predictors of mortality has not been well established. The influence of short-
term fluctuating symptoms can mask the effect of clinically relevant longer-term 
symptoms, compromising the reliability of the observed association of baseline LUTS 
on subsequent morbidity. To provide more robust estimates, we explored the impact of 
LUTS on mortality utilizing repeated assessments of these symptoms and associated 
comorbidities. Our results showed that men with nocturia or daytime frequency have 
increased mortality, even after adjustment for behavioral risk factors and 
comorbidities. However, the associations were significant only in analyses where the 
symptoms and comorbidities were updated every five years indicating that the baseline 
assessments of LUTS are reliable only in predicting short-term mortality risk while 
repeated assessments are needed to predict longer-term risk. 
The crude death rates were higher in men with LUTS throughout the follow-up. After 
adjusting for age and comorbidities, daytime frequency and nocturia remained 
associated with mortality compared with men free of these symptoms. Although an 
association with mortality was more apparent for daytime frequency and nocturia than 
urgency, there was indication of an association of urinary urgency with an elevated 
death risk confined to non-smokers. In men with urinary urgency, and lacking the 
confounding effect of smoking — a commonly recognized risk factor for several 
illnesses such as cardiovascular diseases — the mortality risk was nearly 1.5-fold. 
Furthermore, we found an indication of urgency being related to increased mortality in 
men without a history of cardiac disease, which suggests that urgency might deserve 
attention as a potential indicator of latent heart disease. 
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Our study provides three important improvements to previous reports of longitudinal 
associations of LUTS with mortality. Firstly, we are not aware of any former study 
utilizing repeated assessments and thus taking into account the fluctuation and 
development of symptoms and comorbidities during follow-up. Secondly, our follow-
up is longer than in any previous study on the topic, and covers more than 500 deaths 
(including >70 deaths among men with each of the LUTS examined). Thirdly, 
although some previous studies have assessed the impact of nocturia and urgency on 
mortality [8,17], we are not aware of any earlier study assessing mortality in relation 
to daytime frequency. Our effect size for mortality associated with nocturia is 
consistent with most previous studies showing, on average, a 1.3-fold risk [8]. 
Similarly, the magnitude of risk associated with urgency is fairly consistent with a 
previous Finnish study of elderly men reporting a 1.9-fold mortality at 10-year follow-
up [17]. 
Regarding the limitations of the study, the nocturia question in DAN-PSS-1 does not 
distinguish one void from two voids per night. Because one nocturnal voiding is often 
considered normal, one or two voids/night are unlikely to distinguish meaningful 
nocturia and thus, ≥3 voids/night was considered a more robust indicator of important  
nocturia. Accordingly, while previous studies for aging men have predominantly used  a 
nocturia case definition of ≥2 vs. 0-1 voids/night in their assessments of mortality, fairly 
consistently showing a nocturia-related excess risk of [8], a previous studya previous study 
did not show a significant association for one nocturnal void with  mortality or significant 
gradient in relative death risk in men with three or more 
compared to those with two voids per night [18].  suggested a gradient in risk of death 
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with nocturia severity [18]. Furthermore, although incidence of nocturia is 
independent of nocturia case definition (≥1, ≥2, or ≥3 voids/night), remission 
frequency increases with more stringent criteria [9]. Due to a more stringent case 
definition in our analyses, remission over time is more likely and repeated assessments 
are therefore crucial. 
Due to the relatively small number of deaths related to specific symptoms, our study 
did not have adequate statistical power to analyse the impact of multiple LUTS in 
combination. However, previous findings suggest that storage symptoms frequently 
overlap and various LUTS are often concomitant [19]. Furthermore, we were unable to 
assess the effect of treatments of LUTS on death. However, few men seek treatment 
for their LUTS [19,20] and response to treatment can be unsatisfactory particularly for 
storage symptoms [2,3,21]. Finally, some residual confounding in our results is likely 
in spite of extensive adjustments with various medical conditions and lifestyle factors.  
While urinary symptoms are common in aging men, they may also be markers of ill 
health. Investigations for underlying comorbidity are warranted particularly in cases of 
persistent and treatment-resistant symptoms. The multifactorial etiology of LUTS 
includes various medical conditions and behavioural factors, besides age-related 
changes in the lower urinary tract such as development of BPH. Although LUTS share 
common etiologic factors, distinction between specific symptoms is important due to 
the different pathophysiologic mechanisms, especially in nocturia, which has been 
recently recognized as a separate clinical entity [22]. The proposed etiologies 
underlying various LUTS include vascular insufficiency of the pelvic floor due to 
atherosclerosis [23,24], systemic inflammation in metabolic syndrome [25], 
15 
neurogenic dysfunction related to diabetes [26], fluid shifts caused by hypertension 
and cardiac failure [27] as well as increased sympathetic activity caused by 
hyperinsulinemia or sleep problems [26,28]. These complex pathways may explain the 
association of LUTS with increased mortality. However, the evidence on the 
usefulness of various LUTS as causal risk factors for mortality is lacking: there is no 
data available on whether treatment of LUTS would decrease mortality e.g. by 
preventing injuries or cardiovascular events to occur [6,7,29]. 
In men aged over 50, the fluctuation of LUTS is common and often relates to benign 
and treatable conditions such as BPH. Respectively, men with persisting symptoms are 
likely to have comorbidities, causing resistance to urological treatments. Although  
various treatments for LUTS have potential to improve the quality of life of elderly  male 
patients, care should be taken not to focus only on treating the symptoms but also  
exporing their general health. Besides having a potential impact on patients’ 
prognosis, interventions for comorbidities and unhealthy lifestyle factors may also  
help LUTS to resolve.  
In conclusion, LUTS are more accurate predictors of short-term than longer-term 
mortality risk among aging men. Repeated assessments are needed to identify 
clinically relevant and persistent symptoms, often associated with ill health. 
Accordingly, middle-aged and elderly men presenting with daytime frequrency or 
nocturia are potentially at a 1.4-fold increased risk of death. Therefore, the 
management of men with LUTS should focus not only on treating the symptoms, but 
also assessing their general health, risk factors and major comorbidities, including pre-
clinical conditions. 
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Supplementary information is available at PCAN’s website. 
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Legends of figures and tables 
Figure 1. Flow chart of mortality rates of men in relation to baseline prevalences and 
periodic incidence and remission rates of urinary urgency, frequency and nocturia. 
Figure 2. Kaplan-Meier curves for men with and without daytime frequency and 
nocturia at the baseline (1994). 
Table 1. Characteristics of men with and without urgency, daytime frequency and 
nocturia at the follow-up midpoint (2004). 
Table 2. Unadjusted and adjusted association of LUTS with all-cause mortality in Cox 
regression analyses using variable values updated every five years (time-dependent 
analysis) and values fixed to the baseline assessment of 1994 (fixed analysis) during 
21-year follow-up.
Table 3. Subgroup analyses for variables with significant interaction in the regression 
models: association of urinary urgency with mortality among smoking and non-
smoking men and among men with and without previously diagnosed cardiac disease. 
Supplementary files: 
Suppl. Table 1. Characteristics of men at various stages of follow-up. 
Suppl. Table 2. Unadjusted and adjusted association of LUTS and covariables with 
all-cause mortality in the follow-up of 21 years – Cox regression analyses with 
variable values updated every five years (time-dependent analysis). 
Suppl. Table 3. Unadjusted and adjusted association of LUTS and covariables with 
all-cause mortality in the follow-up of 21 years - Cox regression analyses with 
variable values fixed to the baseline assessment of 1994 (fixed analysis). 
Suppl. Table 4. P-values of interaction terms in regression analyses of 
the association of LUTS with all-cause mortality. 
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 Tables 
Urgency Daytime frequency Nocturia 
Yes No Yes No Yes No 
n % n % n % n % n % n % 
Number of men 190 877 82 985 100 967 
Year of birth 
1944 66 34.7 432 49.5 34 41.5 464 47.1 25 25.0 473 48.9 
1934 84 44.2 328 37.4 33 40.2 379 38.5 44 44.0 368 38.1 
1924 40 21.1 117 13.3 15 18.3 142 14.4 31 31.0 126 13.0 
Marital status 
Married/cohabiting 148 77.9 717 81.8 63 76.8 802 81.4 81 81.0 784 81.1 
Single/divorced 33 17.4 111 12.7 15 18.3 129 13.1 15 15.0 129 13.3 
Widowed 9 4.7 49 5.6 4 4.9 54 5.5 4 4.0 54 5.6 
BMI 
≤25 60 31.6 289 33.0 21 25.6 328 33.3 36 36.0 313 32.4 
25-30 89 46.8 431 49.1 39 47.6 481 48.8 51 51.0 469 48.5 
>30 41 21.6 157 17.9 22 26.8 176 17.9 13 13.0 185 19.1 
Current smoking 28 14.7 121 13.8 9 11.0 140 14.2 12 12.0 137 14.2 
Alcohol intake >150 g/week 38 20 134 15.3 8 9.8 164 16.6 8 8.0 164 17.0 
Medical conditions
Diabetes 35 18.4 93 10.6 15 18.3 113 11.5 15 15.0 113 11.7 
Hypertension 101 53.2 391 44.6 47 57.3 445 45.2 46 46.0 446 46.1 
Cardiac disease 60 31.6 188 21.4 26 31.7 222 22.5 32 32.0 216 22.3 
Pulmonary
disease 27 14.2 99 11.3 8 9.8 118 12.0 19 19.0 107 11.1 
Cerebrovascular disease 16 8.4 48 5.5 9 11.0 55 5.6 8 8.0 56 5.8 
Cancer 22 11.6 79 9.0 8 9.8 93 9.4 18 18.0 83 8.6 
Neurological disease 13 6.8 27 3.1 5 6.1 35 3.6 6 6.0 34 3.5 
Table 1. Characteristics of men with and without urgency, daytime frequency and nocturia at the 
follow-up midpoint (2004).
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Urgency Frequency Nocturia 
HR 95% CI HR 95% CI HR 95% CI 
Time-dependent 
analysis 
Unadjusted 1.71 1.36-2.14 1.95 1.52-2.49 2.31 1.79-2.98 
Adjusted a 1.19 0.94-1.50 1.42 1.11-1.83 1.38 1.07-1.79 
Fixed analysis 
Unadjusted 1.52 0.86-2.69 1.43 1.11-1.84 2.56 1.81-3.63 
Adjusted b 0.94 0.52-1.68 1.09 0.84-1.42 1.41 0.99-2.02 
Table 2. Unadjusted and adjusted association of LUTS with all-cause mortality in Cox 
regression analyses using variable values updated every five years (time-dependent analysis) 
and values fixed to the baseline assessment of 1994 (fixed analysis). 
a A regression model including the year of birth and following categorical variables with time-varying 
values: LUTS, marital status, BMI, smoking, alcohol consumption, diabetes, hypertension, cardiac 
disease, pulmonary disease, cerebrovascular disease, neurological disease and cancer. “Last observation 
carried forward” method [14] used for comorbidities with missing values in the follow-up rounds. 
b All above-mentioned variables treated as fixed categorical variables in the regression model i.e. the 
variable values fixed to the baseline assessment of 1994.  
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Unadjusted Adjusted a
HR 95% CI HR 95% CI 
Current smoking 
Yes 0.95 0.60-1.51 0.73 0.45-1.20
No 2.09 1.61-2.71 1.46 1.12-1.91 
Cardiac disease 
Yes 1.20 0.86-1.69 1.04 0.73-1.48 
No 2.11 1.55-2.86 1.30 0.95-1.79
Table 3. Subgroup analyses for variables with significant interaction in the regression models: 
association of urinary urgency with mortality among smoking and non-smoking men and 
among men with and without previously diagnosed cardiac disease. 
a A regression model including the year of birth and following categorical variables with time-varying 
values: LUTS, marital status, BMI, smoking, alcohol consumption, diabetes, hypertension, cardiac 
disease, pulmonary disease, cerebrovascular disease, neurological disease and cancer. “Last observation 
carried forward” method [14] used for comorbidities with missing values in the follow-up rounds. 
Figure 1. Flow chart of mortality rates of men according to periodic LUTS status. 
a Assessed with a modified question in 1994.  
Figure 2. Kaplan-Meier curves for men with and without daytime frequency and nocturia at 
the baseline (1994).  


